What Is Wegovy? Everything You Should Know Before Starting

Wegovy at a glance:

• Drug class: GLP-1 receptor agonist
• Manufacturer: Novo Nordisk
• FDA approved: 2021
• Route: subcutaneous injection (single-dose pen)
• Typical frequency: once weekly
• Half-life: approximately 7 days
• Cash price (US): $1,300-$1,400/month without insurance
• Receptor target: GLP-1 receptor

Wegovy has become one of the more talked-about names in the glp-1 receptor agonist space. The clinical reality is more nuanced than the headlines suggest, and most of what matters fits in a few sentences. Wegovy is semaglutide labeled and dosed for weight loss.

What is Wegovy?

Wegovy is semaglutide labeled and dosed for weight loss. It targets the same GLP-1 receptor pathways as Ozempic but at a higher target dose (2.4 mg weekly) to maximize appetite suppression and weight reduction.

Wegovy is manufactured by Novo Nordisk and is a brand name for the generic compound semaglutide. Wegovy was approved by the FDA in 2021. Its approved indications include chronic weight management in adults with obesity or overweight with comorbidities, weight management in adolescents 12+ with obesity, cardiovascular risk reduction in adults with overweight/obesity and established CVD. Off-label use happens in clinical practice but is the prescriber's responsibility.

The drug class glp-1 receptor agonist works by acting at the GLP-1 receptor. Here's what to expect.

How Wegovy Works in the Body

Wegovy is semaglutide labeled and dosed for weight loss. It targets the same GLP-1 receptor pathways as Ozempic but at a higher target dose (2.4 mg weekly) to maximize appetite suppression and weight reduction. The receptor target — GLP-1 receptor — drives the downstream effects users care about: mean weight loss of 14.9% of body weight at 68 weeks in step 1 (vs 2.4% on placebo). cardiovascular benefit demonstrated in select.

The pharmacokinetics matter for daily use. Wegovy has a half-life of approximately 7 days, which determines how often it is dosed. The standard route of administration is subcutaneous injection (single-dose pen), and the typical schedule is once weekly.

For more detail on the underlying biology, see our breakdown of how Wegovy works.

Who Uses Wegovy?

Wegovy is most relevant for people whose situation maps to its approved indications: chronic weight management in adults with obesity or overweight with comorbidities; weight management in adolescents 12+ with obesity; cardiovascular risk reduction in adults with overweight/obesity and established CVD.

People who should avoid Wegovy include those with the following:

• personal or family history of medullary thyroid carcinoma
• MEN 2 syndrome
• pregnancy

Common and Serious Side Effects

The most commonly reported side effects of Wegovy include:

• nausea
• diarrhea
• vomiting
• constipation
• abdominal pain
• fatigue
• dizziness

Serious risks — uncommon but worth knowing — include:

• pancreatitis
• gallbladder disease
• thyroid C-cell tumors (boxed warning)
• acute kidney injury
• suicidal ideation (post-marketing reports)

We have a more detailed breakdown in our Wegovy side-effects guide.

Wegovy vs Alternatives

Common alternatives include Zepbound (tirzepatide, larger weight loss in head-to-head), Saxenda (liraglutide, daily injection), and compounded semaglutide (off-label). If you are weighing Wegovy against another option, our comparison pages include Wegovy Side Effects: 7 Things to Watch For (and How to Manage Them), Wegovy Results: Realistic Expectations vs. Trial Headlines, Why Wegovy Costs So Much (and 5 Ways to Pay Less).

Bottom Line

Wegovy fits into a broader landscape of glp-1 receptor agonist options. The right choice for any individual depends on insurance, side-effect tolerance, dosing preference, and prescriber familiarity — usually more than on the molecule itself. Multiple randomized controlled trials support its efficacy. If you are considering Wegovy, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• Wegovy Side Effects: 7 Things to Watch For (and How to Manage Them)
• Wegovy Results: Realistic Expectations vs. Trial Headlines
• Why Wegovy Costs So Much (and 5 Ways to Pay Less)
• The Wegovy Dose Question Everyone Asks (Finally Answered)
• What Is Ozempic? Everything You Should Know Before Starting
• Is Ozempic Safe? An Honest Look at the Side-Effect Profile

Sources

• Marso SP et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6). NEJM 2016;375:1834.
• Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). NEJM 2015;373:11.
• Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.